The IPKat

Thinking beyond the sequence: CAR-T cell therapy litigation at the UPC (2seventy bio v Johnson & Johnson, UPC_CFI_029/2026)

Navigating the complex LNP IP landscape

Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell)

The validity and value of cell therapy safety protocol inventions (T 1555/23)

A new way to define T cells and what it means for cell therapy IP

The reproducibility challenge for advanced therapies (T 0827/23)

Pitfalls of cell therapy manufacturing IP - A case study (T 0868/23)